DOV Pharmaceutical, Inc. (OTCBB: DOVP) announced that it has initiated a Phase II clinical trial of DOV 21,947 in patients diagnosed with major depressive disorder. DOV 21,947 is DOV’s lead triple reuptake inhibitor, or “TRIP,” for the treatment of depression and obesity.


Fatal error: Call to undefined function is_syndicated() in /home/meddisco/public_html/wp-content/themes/executive-pro/single.php on line 32